Feed IMMX
IM

Immix Biopharma, Inc.

IMMX · NASDAQ

$12.14 -5.60% (-$0.72)
1M +11.17%
Market Cap $690.9M
P/E Ratio -
Div. Yield -
ROE 38.44%

Bulios Fair Price

$7.64

37.1% downside

Trenutna cena

$12.14

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica IMMX trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
2/9
Valuation
66 /100
Fair
P/B 3.02x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing
Book val. growth 92.45%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A
Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor
ROIC 18.20%
ROE 38.44%
ROA 16.69%
Debt
100 /100
Low
Debt/Equity 0.00x
Current ratio 25.13x
Int. coverage N/A
Stability
28 /100
Unstable
Beta 0.11x
EPS volatility 32.73%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o IMMX
Online

O podjetju

Immix Biopharma, Inc. is a biotechnology company focused on researching and developing novel therapeutic treatments in the field of cancer immunotherapy. Their main focus is on harnessing the body's immune system to fight cancer through innovative treatment approaches, such as antigen-specific T-cell therapies. The company is developing and testing new therapeutic agents aimed at improving treatment efficacy and reducing side effects in patients with various types of cancer. Their research aims to identify and target specific molecules and processes that are crucial for immune response and regulatory mechanisms in combating cancerous diseases. Shares of Immix Biopharma, Inc. may be of interest to investors following innovations in cancer treatment and seeking investment opportunities in the biotechnology sector.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Ilya Rachman

Employees

21

Headquarters

Los Angeles

Prihajajoči dogodki

06 NOV.

Earnings

Upcoming earnings report

55d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.